Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Study Suggests Preseason Shoulder Strength May Determine Injury Severity For Baseball Pitchers
Athletic injuries can derail any player"s ability to compete, but for a baseball pitcher his shoulder strength and control is critical. A new study to be presented at the American Orthopaedic Society for Sports Medicine"s (AOSSM) Annual Meeting in Keystone, Colorado, suggests that testing a pitcher"s shoulder strength through a series of exercises during the preseason may help create a focused strength training program to prevent serious injury during the season.
generic viagra online
Cardium Presents Gene Activated Matrix Technology And Update On Excellarate Clinical Development Program At ASGT Annual Meeting
Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) announced a presentation entitled "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic Ulcers" at the Late Stage Industry Clinical Trials Symposium at the American Society of Gene Therapy (ASGT) Annual meeting in San Diego, California, on May 27, 2009. Dr. Barbara K. Sosnowski, Cardium"s Vice President of Biologics Development and the Chief Operating Officer of Cardium"s Tissue Repair Company Operating Unit, provided an update on TRC"s Phase 2b MATRIX clinical trial and the new formulation of the Excellarate(TM) product candidate, as well as an overview of the prior clinical study of Excellarate. Drugshop to buy zoloft online and other pills.
News of the day
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression In Rheumatoid Arthritis Models By Selective Inhibition Of The Immunoproteasome
Proteolix, Inc. announced that in an article published in Nature Medicine, Proteolix"s selective immunoproteasome inhibitor PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely eliminate visible signs of disease at the highest dose. The anti-inflammatory effect induced by PR-957 was rapid and long-lasting, lowering expression of multiple inflammatory mediators, including TNF-a and IL-6. Disease regression was evident 24 hours after dosing and a complete amelioration of disease was achieved with a single dose. When compared to anti-TNF-a therapy (etanercept), PR-957 mediated a more rapid resolution of clinical symptoms, including joint inflammation, and was more effective than etanercept in a model of aggressive arthritis.
Endocrinology

BioTech Medics Announces SHBAN Antiviral Solution Undergoing H1N1 (Swine) Influenza Efficacy Testing

BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has contracted to start conducting independent clinical testing of its patented SHBAN™ Antiviral Hand Sanitizer Solution to prove it kills the H1N1 (Swine) Influenza A virus in compliance with FDA and EPA standards. In 2007 BioTech conducted an independent study to determine the efficacy of virucidal SHBAN against Avian H5N1 Influenza NIBRG-14 Virus (also known as the Avian Bird Flu). BioTech reported that the SHBAN Solution had clinically proven its anti-viral properties and had topically killed the Avian Influenza virus. Significantly, SHBAN was proven non-toxic with "no cytotoxicity observed on the MDCK cell line after treatment." SHBAN is a bio-degradable product superior to most anti-viral and anti-bacterial disinfectants because 1) SHBAN is longer lasting, SHBAN does not evaporate within 15 seconds after application and cease working (like alcohol gels); 2) SHBAN is non-toxic when used as directed on humans and animals; 3) SHBAN is non-staining, non-bleaching; 4) SHBAN is non-flammable and 5) SHBAN has no harmful or toxic odors. Most hand sanitizer products cannot make all of these claims. BioTech currently sells a 3 oz SHBAN™ Go Anywhere Hand Atomizer Spray Bottle that complies with TSA carry-on travel regulations. SHBAN sales are up significantly in 2009. BioTech is releasing this Fall 1 oz and 16 oz bottles together with SHBAN Hand Wipe Towelettes. The World Health Organization (WHO) has declared the H1N1 Influenza a worldwide pandemic 6, so it is essential that people buying hand sanitizers know that SHBAN can prove that SHBAN kills the H1N1 Influenza Virus on the hands. SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711 and #5,585,391 and pending international patents. SHBAN is a trademark of BioTech Medics, Inc. BioTech is seeking and negotiating USA and foreign distributorships at this time. SHBAN™ in previous in vitro and in vivo testing has been evaluated for its antimicrobial properties against Staph. Aureus, Staph. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. BioTech Medics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009